{"transactions":[{"id":2175419,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:27:43.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.81,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-22-029674","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029674/doc4.xml","form_type":"4"}},{"id":2175418,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:27:43.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.53,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-22-029674","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029674/doc4.xml","form_type":"4"}},{"id":2175417,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:27:43.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":3.93,"underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000899243-22-029674","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029674/doc4.xml","form_type":"4"}},{"id":2175416,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:27:43.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":5.99,"underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000899243-22-029674","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029674/doc4.xml","form_type":"4"}},{"id":2175415,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:27:43.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":28.1,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-029674","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029674/doc4.xml","form_type":"4"}},{"id":2175414,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:27:43.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":19.19,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-029674","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029674/doc4.xml","form_type":"4"}},{"id":2175413,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:27:43.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":28.24,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-029674","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029674/doc4.xml","form_type":"4"}},{"id":2175412,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:27:43.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":19.69,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-029674","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029674/doc4.xml","form_type":"4"}},{"id":2175411,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:27:43.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":8.52,"underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000899243-22-029674","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029674/doc4.xml","form_type":"4"}},{"id":2435293,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-14T21:00:32.000Z","date":"2022-01-12","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest and become exercisable on January 12, 2023 subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":30000,"derivative":{"exercise_price":4.81,"expiration_date":"2032-01-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-22-003406","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122003406/doc4.xml","form_type":"4"}},{"id":2947306,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-14T16:21:04.000Z","date":"2020-12-10","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years."}],"balance_after":30000,"derivative":{"exercise_price":4.53,"expiration_date":"2030-12-10","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000920465-20-000164","document":"wf-form4_160798084563120.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046520000164/wf-form4_160798084563120.xml","form_type":"4"}},{"id":2949769,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-10T16:04:50.000Z","date":"2020-12-08","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration (\"FDA\") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":15000,"derivative":{"exercise_price":16.52,"expiration_date":"2030-12-08","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-062687","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555089/000120919120062687/doc4.xml","form_type":"4"}},{"id":3333019,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-23T16:10:00.000Z","date":"2019-12-20","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 12,000 shares of the Issuer's Common Stock which shall be fully vested and exercisable on December 20, 2020."}],"balance_after":12000,"derivative":{"exercise_price":3.93,"expiration_date":"2029-12-20","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000920465-19-000184","document":"wf-form4_157713538237981.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046519000184/wf-form4_157713538237981.xml","form_type":"4"}},{"id":3343411,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-12T18:21:13.000Z","date":"2019-12-10","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration (\"FDA\") approval of tesetaxel; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":12500,"derivative":{"exercise_price":30.51,"expiration_date":"2029-12-10","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-19-060278","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555089/000120919119060278/doc4.xml","form_type":"4"}},{"id":3687276,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-25T21:55:09.000Z","date":"2019-01-23","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 12,000 shares of the Issuer's Common Stock which shall be fully vested and exercisable on January 23, 2020."}],"balance_after":12000,"derivative":{"exercise_price":5.99,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000920465-19-000017","document":"wf-form4_154847128571028.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046519000017/wf-form4_154847128571028.xml","form_type":"4"}},{"id":3707480,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-03T20:04:56.000Z","date":"2018-12-31","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest and become exercisable on December 31, 2019, subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":12500,"derivative":{"exercise_price":14.08,"expiration_date":"2028-12-31","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-19-001510","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555089/000120919119001510/doc4.xml","form_type":"4"}},{"id":3728051,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-12-19T01:09:58.000Z","date":"2018-12-15","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant."}],"balance_after":300000,"derivative":{"exercise_price":24.97,"expiration_date":"2028-12-15","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001209191-18-063353","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919118063353/doc4.xml","form_type":"4"}},{"id":3877227,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-07-04T01:01:57.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":95531,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"At the date of filing, 412,500 shares of the options granted pursuant to the underlying awards were fully vested and exercisable."}],"balance_after":600000,"derivative":{"exercise_price":7.2,"expiration_date":"2023-05-01","underlying":"Common Stock","underlying_shares":95531},"source":{"system":"sec-edgar","filing":"0001209191-18-041384","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/doc4.xml","form_type":"4"}},{"id":3877226,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-07-04T01:01:57.000Z","date":"2018-06-29","kind":"exercise","acquired":false,"shares":129469,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"At the date of filing, 412,500 shares of the options granted pursuant to the underlying awards were fully vested and exercisable."}],"balance_after":695531,"derivative":{"exercise_price":7.2,"expiration_date":"2023-05-01","underlying":"Common Stock","underlying_shares":129469},"source":{"system":"sec-edgar","filing":"0001209191-18-041384","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/doc4.xml","form_type":"4"}},{"id":3877225,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2018-07-04T01:01:57.000Z","date":"2018-07-02","kind":"sale","acquired":false,"shares":3400,"price":38.7544,"value":131764.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The range of sales prices received was $38.55 to $38.85. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price."}],"balance_after":2640,"source":{"system":"sec-edgar","filing":"0001209191-18-041384","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/doc4.xml","form_type":"4"}},{"id":3877224,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2018-07-04T01:01:57.000Z","date":"2018-07-02","kind":"sale","acquired":false,"shares":92131,"price":38.1296,"value":3512918.1776,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The range of sales prices received was $37.50 to $38.50. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price."}],"balance_after":6040,"source":{"system":"sec-edgar","filing":"0001209191-18-041384","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/doc4.xml","form_type":"4"}},{"id":3877223,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2018-07-04T01:01:57.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":95531,"price":7.2,"value":687823.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018."}],"balance_after":98171,"source":{"system":"sec-edgar","filing":"0001209191-18-041384","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/doc4.xml","form_type":"4"}},{"id":3877222,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2018-07-04T01:01:57.000Z","date":"2018-06-29","kind":"sale","acquired":false,"shares":2112,"price":41.3899,"value":87415.4688,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The range of sales prices received was $41.075 to $41.45. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price."}],"balance_after":2640,"source":{"system":"sec-edgar","filing":"0001209191-18-041384","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/doc4.xml","form_type":"4"}},{"id":3877221,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2018-07-04T01:01:57.000Z","date":"2018-06-29","kind":"sale","acquired":false,"shares":51696,"price":40.1694,"value":2076597.3024,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The range of sales prices received was $39.775 to $40.70. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price."}],"balance_after":4752,"source":{"system":"sec-edgar","filing":"0001209191-18-041384","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/doc4.xml","form_type":"4"}},{"id":3877220,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2018-07-04T01:01:57.000Z","date":"2018-06-29","kind":"sale","acquired":false,"shares":75661,"price":39.1367,"value":2961121.8587,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The range of sales prices received was $38.75 to $39.75. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price."}],"balance_after":56448,"source":{"system":"sec-edgar","filing":"0001209191-18-041384","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/doc4.xml","form_type":"4"}},{"id":3877219,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2018-07-04T01:01:57.000Z","date":"2018-06-29","kind":"exercise","acquired":true,"shares":129469,"price":7.2,"value":932176.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018."}],"balance_after":132109,"source":{"system":"sec-edgar","filing":"0001209191-18-041384","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/doc4.xml","form_type":"4"}},{"id":4106683,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-04T20:55:25.000Z","date":"2018-01-02","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 12,500 shares of the Issuer's Common Stock, which shall be fully vested and exercisable on January 2, 2019."}],"balance_after":12500,"derivative":{"exercise_price":24.73,"expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-18-002271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555089/000120919118002271/doc4.xml","form_type":"4"}},{"id":4125517,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-12-20T21:16:10.000Z","date":"2017-12-18","kind":"grant","acquired":true,"shares":310000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant."}],"balance_after":310000,"derivative":{"exercise_price":17,"expiration_date":"2027-12-18","underlying":"Common Stock","underlying_shares":310000},"source":{"system":"sec-edgar","filing":"0001209191-17-066629","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919117066629/doc4.xml","form_type":"4"}},{"id":4133861,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-13T21:06:13.000Z","date":"2017-12-11","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, which shall be fully vested and exercisable on December 11, 2018."}],"balance_after":10000,"derivative":{"exercise_price":28.1,"expiration_date":"2027-12-11","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000920465-17-000079","document":"wf-form4_151321715936457.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046517000079/wf-form4_151321715936457.xml","form_type":"4"}},{"id":4496927,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-06T18:22:35.000Z","date":"2017-01-04","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock which shall be fully vested and exercisable on January 4, 2018."}],"balance_after":10000,"derivative":{"exercise_price":19.19,"expiration_date":"2027-01-04","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000920465-17-000014","document":"wf-form4_148374494293531.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046517000014/wf-form4_148374494293531.xml","form_type":"4"}},{"id":4512840,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":124311,"kind":"person","name":"Rosen Robert","position":1,"cik":"0001555089","reported_name":"Rosen Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-12-23T21:05:42.000Z","date":"2016-12-21","kind":"grant","acquired":true,"shares":310000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant."}],"balance_after":310000,"derivative":{"exercise_price":13,"expiration_date":"2026-12-21","underlying":"Common Stock","underlying_shares":310000},"source":{"system":"sec-edgar","filing":"0001209191-16-156662","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919116156662/doc4.xml","form_type":"4"}}]}